Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial.

Quinn TJ, Daignault-Newton S, Bosch W, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, DeWeese T, Gay HA, Michalski J, Hamstra DA.

Pract Radiat Oncol. 2020 Jan 21. pii: S1879-8500(20)30004-7. doi: 10.1016/j.prro.2019.12.011. [Epub ahead of print]

PMID:
31978591
2.

A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.

Fischer-Valuck BW, Gay HA, Patel S, Baumann BC, Michalski JM.

Front Oncol. 2019 Dec 10;9:1378. doi: 10.3389/fonc.2019.01378. eCollection 2019. Review.

3.

Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma.

Brenneman RJ, Sharifai N, Fischer-Valuck B, Hassanzadeh C, Guzelian J, Chrisinger JSA, Michalski JM, Oppelt P, Baumann BC.

Front Oncol. 2019 Sep 26;9:922. doi: 10.3389/fonc.2019.00922. eCollection 2019.

4.

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.

Barnes J, Kennedy WR, Fischer-Valuck BW, Baumann BC, Michalski JM, Gay HA.

J Contemp Brachytherapy. 2019 Aug;11(4):320-328. doi: 10.5114/jcb.2019.86974. Epub 2019 Aug 29.

5.

Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer.

Spratt DE, Michalski JM.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):798-800. doi: 10.1016/j.ijrobp.2019.04.001. No abstract available.

PMID:
31204661
6.

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer.

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, Smith ZL, Andriole GL, Arora V, Bullock A, Carmona R, Figenshau RS, Grubb RL, Guzzo TJ, Knoche EM, Malkowicz SB, Mamtani R, Pachynski RK, Roth BJ, Zaghloul MS, Gay HA, Baumann BC.

Cancer Med. 2019 Jul;8(8):3698-3709. doi: 10.1002/cam4.2102. Epub 2019 May 22.

7.

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM.

Radiother Oncol. 2019 Jun;135:19-24. doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5.

PMID:
31015166
8.

First Reported Case of Pediatric Radiation Treatment With Magnetic Resonance Image Guided Radiation Therapy.

Henke LE, Green OL, Schiff J, Rodriguez VL, Mutic S, Michalski J, Perkins SM.

Adv Radiat Oncol. 2019 Jan 31;4(2):233-236. doi: 10.1016/j.adro.2019.01.008. eCollection 2019 Apr-Jun. No abstract available.

9.

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM.

J Clin Oncol. 2019 May 10;37(14):1159-1168. doi: 10.1200/JCO.18.02158. Epub 2019 Mar 12.

PMID:
30860948
10.

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.

Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Pisansky TM, Chen Y, Sandler HM, Movsas B.

JAMA Oncol. 2019 May 1;5(5):664-670. doi: 10.1001/jamaoncol.2018.6752. Erratum in: JAMA Oncol. 2019 Apr 4;:.

PMID:
30763425
11.

NCTN Assessment on Current Applications of Radiomics in Oncology.

Nie K, Al-Hallaq H, Li XA, Benedict SH, Sohn JW, Moran JM, Fan Y, Huang M, Knopp MV, Michalski JM, Monroe J, Obcemea C, Tsien CI, Solberg T, Wu J, Xia P, Xiao Y, El Naqa I.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):302-315. doi: 10.1016/j.ijrobp.2019.01.087. Epub 2019 Jan 31. Review.

PMID:
30711529
12.

Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.

Henke LE, Olsen JR, Contreras JA, Curcuru A, DeWees TA, Green OL, Michalski J, Mutic S, Roach MC, Bradley JD, Parikh PJ, Kashani R, Robinson CG.

Adv Radiat Oncol. 2018 Oct 18;4(1):201-209. doi: 10.1016/j.adro.2018.10.003. eCollection 2019 Jan-Mar.

13.

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.

Fischer-Valuck BW, Michalski JM, Contreras JA, Brenneman R, Christodouleas JP, Abraham CD, Kim EH, Arora VK, Bullock AD, Carmona R, Figenshau RS, Grubb R 3rd, Knoche EM, Pachynski RK, Picus J, Roth BJ, Sargos P, Andriole GL, Gay HA, Baumann BC.

Clin Transl Radiat Oncol. 2018 Dec 12;15:38-41. doi: 10.1016/j.ctro.2018.12.001. eCollection 2019 Feb.

14.

Stereotactic Body Radiation Therapy for the Treatment of Primary Cardiac Angiosarcoma Causing Hemodynamic Instability.

Gabani P, Fischer-Valuck BW, Robinson CG, Wilson DB, Michalski JM.

Pract Radiat Oncol. 2019 Jan;9(1):5-8. doi: 10.1016/j.prro.2018.07.004. No abstract available.

PMID:
30611463
15.

Detecting a Survival Benefit to Dose Escalation-Reply.

Dignam JJ, Winter KA, Michalski J.

JAMA Oncol. 2019 Jan 1;5(1):110. doi: 10.1001/jamaoncol.2018.5093. No abstract available.

PMID:
30452496
16.

The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols.

FitzGerald TJ, Bishop-Jodoin M, Laurie F, O'Meara E, Davis C, Bogart J, Kalapurakal J, Siegel MJ, Chakravarthy B, Okunieff P, Haffty B, Michalski J, Ulin K, Followill DS, Kry S, Knopp M, Zhang J, Rosen D, Rosen M, Xiao Y, Schwartz L, Moni J, Cicchetti MG.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):775-782. doi: 10.1016/j.ijrobp.2018.08.039. Epub 2018 Oct 18. Review.

17.

Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial.

Hwang EI, Kool M, Burger PC, Capper D, Chavez L, Brabetz S, Williams-Hughes C, Billups C, Heier L, Jaju A, Michalski J, Li Y, Leary S, Zhou T, von Deimling A, Jones DTW, Fouladi M, Pollack IF, Gajjar A, Packer RJ, Pfister SM, Olson JM.

J Clin Oncol. 2018 Oct 17:JCO2017764720. doi: 10.1200/JCO.2017.76.4720. [Epub ahead of print]

PMID:
30332335
18.

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.

Lancet Oncol. 2018 Nov;19(11):1504-1515. doi: 10.1016/S1470-2045(18)30528-X. Epub 2018 Oct 10. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

19.

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M 3rd, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343. doi: 10.1016/j.ijrobp.2018.09.039. Epub 2018 Oct 9.

PMID:
30312717
20.

Radiation Therapy for Prostate Cancer.

Gay HA, Michalski JM.

Mo Med. 2018 Mar-Apr;115(2):146-150.

21.

Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.

Xiao C, Moughan J, Movsas B, Konski AA, Hanks GE, Cox JD, Roach M 3rd, Zeitzer KL, Lawton CA, Peters CA, Rosenthal SA, Hsu IJ, Horwitz EM, Mishra MV, Michalski JM, Parliament MB, D'Souza DP, Pugh SL, Bruner DW.

Adv Radiat Oncol. 2018 Jun 7;3(3):405-411. doi: 10.1016/j.adro.2018.04.010. eCollection 2018 Jul-Sep.

22.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
23.

Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival.

Fischer-Valuck BW, Baumann BC, Apicelli A, Rao YJ, Roach M, Daly M, Dans MC, White P, Contreras J, Henke L, Gay H, Michalski JM, Abraham C.

Cancer Med. 2018 Sep;7(9):4240-4250. doi: 10.1002/cam4.1655. Epub 2018 Aug 17.

24.

Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter?

Germino E, Fischer-Valuck BW, Rudra S, Rao YJ, Contreras J, Abraham C, Michalski J, Gay H.

Bladder Cancer. 2018 Jul 30;4(3):311-317. doi: 10.3233/BLC-180165.

25.

Intensity-modulated radiotherapy for prostate cancer.

Fischer-Valuck BW, Rao YJ, Michalski JM.

Transl Androl Urol. 2018 Jun;7(3):297-307. doi: 10.21037/tau.2017.12.16. Review.

26.

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.

Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M 3rd, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):287-295. doi: 10.1016/j.ijrobp.2018.06.008. Epub 2018 Jun 18.

27.

Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: A propensity score-matched analysis.

Markovina S, Meeks MW, Badiyan S, Vetter J, Gay HA, Paradis A, Michalski J, Sandhu G.

Adv Radiat Oncol. 2017 Dec 13;3(2):190-196. doi: 10.1016/j.adro.2017.12.001. eCollection 2018 Apr-Jun.

28.

Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer.

Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, Choy H.

JAMA Oncol. 2018 Sep 1;4(9):1287-1288. doi: 10.1001/jamaoncol.2018.1258. No abstract available.

29.

Practical Implications of Ferromagnetic Artifacts in Low-field MRI-guided Radiotherapy.

Green O, Henke LE, Parikh P, Roach MC, Michalski JM, Gach HM.

Cureus. 2018 Mar 22;10(3):e2359. doi: 10.7759/cureus.2359.

30.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Luh JY, Finkelstein SE, Michalski JM, Sandler H.

Ann Intern Med. 2018 Apr 17;168(8):607-608. doi: 10.7326/L17-0734. No abstract available.

PMID:
29677258
31.

National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury.

Haas-Kogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, Flampouri S, MacDonald S, Fouladi M, Stephen K, Kalapurakal J, Terezakis S, Kooy H, Grosshans D, Makrigiorgos M, Mishra K, Poussaint TY, Cohen K, Fitzgerald T, Gondi V, Liu A, Michalski J, Mirkovic D, Mohan R, Perkins S, Wong K, Vikram B, Buchsbaum J, Kun L.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):152-168. doi: 10.1016/j.ijrobp.2018.01.013. Review.

32.

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H.

JAMA Oncol. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039. Epub 2018 Jun 14.

33.

Association of 1p/19q Codeletion and Radiation Necrosis in Adult Cranial Gliomas After Proton or Photon Therapy.

Acharya S, Robinson CG, Michalski JM, Mullen D, DeWees TA, Campian JL, Chundury A, Bottani B, Hallahan DE, Bradley JD, Huang J.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):334-343. doi: 10.1016/j.ijrobp.2018.01.099. Epub 2018 Feb 9.

PMID:
29534896
34.

American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology.

Mayo CS, Moran JM, Bosch W, Xiao Y, McNutt T, Popple R, Michalski J, Feng M, Marks LB, Fuller CD, Yorke E, Palta J, Gabriel PE, Molineu A, Matuszak MM, Covington E, Masi K, Richardson SL, Ritter T, Morgas T, Flampouri S, Santanam L, Moore JA, Purdie TG, Miller RC, Hurkmans C, Adams J, Jackie Wu QR, Fox CJ, Siochi RA, Brown NL, Verbakel W, Archambault Y, Chmura SJ, Dekker AL, Eagle DG, Fitzgerald TJ, Hong T, Kapoor R, Lansing B, Jolly S, Napolitano ME, Percy J, Rose MS, Siddiqui S, Schadt C, Simon WE, Straube WL, St James ST, Ulin K, Yom SS, Yock TI.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1057-1066. doi: 10.1016/j.ijrobp.2017.12.013. Epub 2017 Dec 15. Review.

35.

NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.

Ali AN, Zhang P, Yung WKA, Chen Y, Movsas B, Urtasun RC, Jones CU, Choi KN, Michalski JM, Fischbach AJ, Markoe AM, Schultz CJ, Penas-Prado M, Garg MK, Hartford AC, Kim HE, Won M, Curran WJ Jr.

J Neurooncol. 2018 Mar;137(1):39-47. doi: 10.1007/s11060-017-2558-x. Epub 2018 Feb 5.

36.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10. Erratum in: JAMA Oncol. 2018 May 1;4(5):751.

37.

A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.

Jackson WC, Dess RT, Litzenberg DW, Li P, Schipper M, Rosenthal SA, Chang GC, Horwitz EM, Price RA, Michalski JM, Gay HA, Wei JT, Feng M, Feng FY, Sandler HM, Wallace RE, Spratt DE, Hamstra DA.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):40-47. doi: 10.1016/j.prro.2017.08.004. Epub 2017 Aug 16.

PMID:
29304991
38.

Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen.

Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S, Parikh P, Olsen J.

Radiother Oncol. 2018 Mar;126(3):519-526. doi: 10.1016/j.radonc.2017.11.032. Epub 2017 Dec 23.

39.

Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience.

Cosper PF, Olsen J, DeWees T, Van Tine BA, Hawkins W, Michalski J, Zoberi I.

Radiat Oncol. 2017 Dec 8;12(1):198. doi: 10.1186/s13014-017-0920-y.

40.

Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408.

Nichols RC, Hu C, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Gore EM, Balogh AG, McGowan D, Michalski J, Raben A, Rudoler S, Jones CU, Sandler H.

Adv Radiat Oncol. 2017 Aug 3;2(4):608-614. doi: 10.1016/j.adro.2017.07.004. eCollection 2017 Oct-Dec.

41.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
42.

Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system.

Fischer-Valuck BW, Henke L, Green O, Kashani R, Acharya S, Bradley JD, Robinson CG, Thomas M, Zoberi I, Thorstad W, Gay H, Huang J, Roach M, Rodriguez V, Santanam L, Li H, Li H, Contreras J, Mazur T, Hallahan D, Olsen JR, Parikh P, Mutic S, Michalski J.

Adv Radiat Oncol. 2017 Jun 1;2(3):485-493. doi: 10.1016/j.adro.2017.05.006. eCollection 2017 Jul-Sep.

43.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
44.

Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial.

Hamstra DA, Mariados N, Sylvester J, Shah D, Gross E, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Daignault-Newton S, Fischer-Valuck BW, Chundury A, Gay HA, Bosch W, Michalski J.

Pract Radiat Oncol. 2018 Jan - Feb;8(1):e7-e15. doi: 10.1016/j.prro.2017.07.008. Epub 2017 Jul 19.

45.

Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.

Fischer-Valuck BW, Rao YJ, Henke LE, Rudra S, Hui C, Baumann BC, Gay HA, Michalski JM.

Eur Urol Focus. 2018 Dec;4(6):900-906. doi: 10.1016/j.euf.2017.09.001. Epub 2017 Sep 14.

PMID:
28919521
46.

Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.

Fischer-Valuck BW, Rao YJ, Rudra S, Przybysz D, Germino E, Samson P, Baumann BC, Gay H, Michalski J.

J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24.

PMID:
28842247
47.

Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Oncol Pract. 2017 Sep;13(9):621-625. doi: 10.1200/JOP.2017.024919. Epub 2017 Aug 10. No abstract available.

PMID:
28796558
48.

Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529.

Olsen JR, Moughan J, Myerson R, Abitbol A, Doncals DE, Johnson D, Schefter TE, Chen Y, Fisher B, Michalski J, Narayan S, Chang A, Crane CH, Kachnic L.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):400-408. doi: 10.1016/j.ijrobp.2017.02.005. Epub 2017 Feb 13.

49.

External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.

Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, Dunn RL, Klein EA, Sandler HM, Saigal CS, Litwin MS, Kuban DA, Hembroff L, Regan MM, Chang P; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium, Michalski JM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):304-317. doi: 10.1016/j.ijrobp.2017.02.019. Epub 2017 Feb 22.

50.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM.

J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26. Erratum in: J Urol. 2017 Nov;198(5):1175.

Supplemental Content

Loading ...
Support Center